Suchergebnisse - "Campbell, Christine"

PubPharm (10)

1

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Moreno-Aspitia, A. | Holmes, E. | Jackisch, C. | +40

2

Circulating Tumor DNA in HER2-Amplified Breast Cancer : A Translational Research Substudy of the NeoALTTO Phase III Trial

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2019

von Rothé, F. | Silva, M. | Venet, D. | +20

3

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer : Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials

enthalten in: Cancer | 2019

von Lambertini, M. | Martel, S. | Campbell, C. | +14

CommentIn: Cancer. 2019 Jan 15;125(2):181-184. - PMID 30500982

4

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

enthalten in: Journal of the National Cancer Institute | 2019

von Lambertini, M. | Campbell, C. | Bines, J. | +19

CommentIn: J Natl Cancer Inst. 2019 Jan 1;111(1):9-10. - PMID 29878141

5

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer : a NeoALTTO sub-study (BIG 1-06)

enthalten in: Breast cancer research and treatment | 2018

von Ponde, N. | Bradbury, I. | Lambertini, M. | +21

6

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)

enthalten in: Breast cancer research and treatment | 2017

von Ponde, N. | Bradbury, I. | Lambertini, M. | +21

7

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)

enthalten in: Breast cancer research and treatment | 2017

von Ponde, N. | Bradbury, I. | Lambertini, M. | +21

8

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial

enthalten in: Journal of the National Cancer Institute | 2016

von Sonnenblick, A. | de Azambuja, E. | Agbor-Tarh, D. | +16

9

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab : A Secondary Analysis of the NeoALTTO Trial

enthalten in: JAMA oncology | 2015

von Salgado, R. | Denkert, C. | Campbell, C. | +13

CommentIn: JAMA Oncol. 2015 Jul;1(4):455-6. - PMID 26181253

10

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2015

von Scaltriti, M. | Nuciforo, P. | Bradbury, I. | +19

1
[1]